Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP7374 (Flublok) in adults ≥61 years
NCT01961960Phase 3Completed
- Sponsor
- UMN Pharma Inc.
- Start
- Oct 2013
- Primary completion
- Nov 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of influenza vaccine in influenza, sponsored by UMN Pharma Inc. Primary endpoint: hemagglutination inhibition antibody titer at Day 29. Started Oct 2013; status: completed.
02
Drugs
influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01961960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961960.